Hyalgan

Hyalgan is a prescription intra‑articular injection that contains sodium hyaluronate as its active ingredient. It is supplied as a sterile solution for injection into the joint space, without a specified strength in the EU market labeling. Hyalgan belongs to the class of viscosupplements and is used to manage symptoms of osteoarthritis, primarily in the knee, by supplementing the joint’s natural hyaluronic acid and may improve joint function.

Hyalgan is indicated for the symptomatic treatment of knee osteoarthritis in adults. It is administered directly into the affected knee joint by a healthcare professional. - Relief of pain associated with knee OA. - Improvement of joint mobility and function. - Delay of need for surgical intervention such as total knee replacement. - Use as an adjunct to physical therapy and other non‑pharmacologic measures. - May be considered when oral analgesics are insufficient or contraindicated. - Single treatment course typically consists of three to five weekly injections.

Adverse reactions to intra‑articular Hyalgan are generally localized to the injection site, though systemic events can occur rarely. Common: - Mild pain or tenderness at the injection site that usually resolves within a few days. - Swelling or effusion of the treated knee, often accompanied by a feeling of fullness. - Warmth or localized redness around the injection area, indicative of a mild inflammatory response. - Transient stiffness lasting several days, which may improve with gentle movement. Serious: - Acute joint infection (septic arthritis) presenting with severe pain, fever, and rapid joint deterioration. - Severe allergic reaction, including urticaria, angio‑edema, or anaphylaxis requiring emergency treatment. - Persistent or worsening joint inflammation that does not improve with standard care. - Rapidly progressive osteoarthritis characterized by accelerated cartilage loss and increased functional limitation.

Before using Hyalgan, clinicians should evaluate patient history and joint condition to minimize risks. - Confirm diagnosis of knee osteoarthritis and rule out active joint infection. - Assess for hypersensitivity to sodium hyaluronate or any component of the injection solution. - Use caution in patients with severe inflammatory arthritis or recent intra‑articular corticosteroid injections. - Evaluate renal function in patients with known kidney disease, as hyaluronate is cleared renally. - Avoid use in pregnant or breastfeeding women unless benefits outweigh potential risks. - Consider postponing treatment in patients with uncontrolled diabetes due to infection risk.

Hyalgan may interact with other agents administered intra‑articularly or systemically; awareness of potential interactions helps ensure safe use. Avoid: - Concurrent intra‑articular corticosteroids or other viscosupplements in the same joint, which can increase risk of infection or diminish efficacy. - Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) when combined with joint aspiration, as bleeding risk may rise. Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may mask early signs of joint infection. - Disease‑modifying antirheumatic drugs (DMARDs) such as methotrexate, which could alter immune response. - Intra‑articular hyaluronate in patients receiving biologic agents (e.g., TNF inhibitors) should be monitored for infection. - High‑dose systemic steroids, which may increase susceptibility to septic arthritis.